Navigation Links
Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
Date:5/17/2012

WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine.  The following distinguished investigators join Dr. Gabriel N. Hortobagyi, MD, FACP (University of Texas MD Anderson Cancer Center), Dr. Kathy D. Miller, MD (Indiana University School of Medicine Melvin and Bren Simon Cancer Center), and Dr. Hope S. Rugo, MD (University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center) on the SAB:

Dr. Keith L. Knutson. PhD
Associate Professor, Department of Immunology
Mayo Clinic

Dr. Knutson's current interests and research focus on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials.  His laboratory research on cancer vaccines focuses on augmenting CD4 helper T cell immunity using peptide epitopes.  These vaccine strategies are aimed at preventing patients from relapsing after optimal conventional therapies.  Adoptive T cell therapy is also being examined, a strategy that involves infusing high numbers of T cells into patients with active bulky malignancy.

In addition to his research, Dr. Knutson participates in and chairs several study sections; is Director of the Mayo Clinic Cancer Center Immunology and Immunotherapy Program; Co-director, Mayo Clinic Immune Monitoring Core; and Director, Ovarian Cancer Immunotherapy Program at Mayo Clinic.

Dr. Knutson received his PhD from the University of Georgia in Physiology and Pharmacology in 1995 and completed two post-doctoral fellowships in immunology: one at the University of British Columbia; and the other at the University of Washington.  He was a 2004 recipient of a Howar
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... WOODCLIFF LAKE, N.J. and SAN ... announced today that its parent company Eisai Co., Ltd. ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. ... and CEO: Dr. Helen Torley , "NASDAQ: HALO") ... eribulin mesylate (brand name: Halaven ® , "eribulin") in ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... the release dated August 24, 2011 with the following ... and should read: The Company will provide attendees an ... Form 8K with the SEC after the close of ...  This presentation will also be available at http://ir.questcor.com/sec.cfm ...
... DOYLESTOWN, Pa., Sept. 1, 2011 ProPhase Labs (NASDAQ: ... be donating $1,000 to a well-deserving, locally nominated and ... their "Share Your Cause, Not Your Cold" contest, hosted ... registered, qualified and valid non-for-profit organization organized under the ...
Cached Medicine Technology:UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 2UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 3Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 2Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 3
(Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... apnea (OSA) and the growing number of individuals who remain undiagnosed, treatment options ... continue to shy away from traditional CPAP therapy due to its overall lack ...
(Date:7/30/2015)... ... ... The Venetian on Grace Bay in the Turks & Caicos Islands is pleased to announce ... 40% on their stay while enjoying some of the most beautiful ocean views in the ... a chance to reconnect with loved ones and rediscover one's best self. The sea ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country see the ... a serious challenge. Because of growing competition, it is more important than ever ... , The team at Wound Care Advantage has found that while ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Two ... people with the rare bone marrow disorder called myelofibrosis. ... brand name Jakafi, won,t cure myelofibrosis, it can help ease ... to the studies. "This is probably the most ...
... report published this week in the New England Journal ... melanoma patients with a specific genetic mutation benefit from the ... to 15.9 months. In patients who responded, the drug stopped ... patients with a BRAF V600 mutation, this drug is a ...
... of Traumatic Brain Injury Research at Kessler Foundation, is an ... on March 6, 2012, in Washington, DC. Dr. Grafman ... brain injury. A well known expert, he will focus on ... injury and genetic polymorphisms on social abilities and quality of ...
... Colin Farrelly wants to see more research into remarkable ... live 100 years disease-free. He describes the current pathology-based ... biology" and suggest more resources should be focused on ... the question ,what causes disease?, is the most significant ...
... -- Strict enforcement of underage drinking laws reduces the ... new study suggests. State lawmakers have relied heavily on ... of alcohol under the legal age laws -- to control ... on young people aged 15 to 24 from the FBI,s ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... FDA mandate that would have forced tobacco companies to ... The proposed requirement from the U.S. Food and Drug ... would have emblazoned cigarette packaging with images of people ...
Cached Medicine News:Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Kessler Foundation neuroscientist addresses 2nd Annual TBI Conference in Washington DC 2Health News:Strict Underage Drinking Laws May Deter Delinquency in Teens 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2
... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
... Designed for High Throughput Screening ... of assays into HTS by sharing ... performance of Analyst AD, fluorescence intensity, ... Optimized for seamless integration into ...
... features for assay development and basic ... Reduces the inevitable transfer time required ... developed to meet the challenges of ... unparalleled detection performance for Fluorescence Intensity, ...
Medicine Products: